STOCK TITAN

[SCHEDULE 13G] Mural Oncology plc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares, nominal value $0.01 per share ("Ordinary Shares") of Mural Oncology plc (the "Issuer") outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G



Prosight Management, LP
Signature:Prosight Partners, LLC
Name/Title:General Partner
Date:06/26/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner
Date:06/26/2025
Prosight Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:06/26/2025
Signature:Prosight Partners, LLC
Name/Title:Sole Manager of the General Partner
Date:06/26/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:06/26/2025
Prosight Plus Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:06/26/2025
Signature:Prosight Partners, LLC
Name/Title:General Partner of the General Partner
Date:06/26/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:06/26/2025
Prosight Partners, LLC
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager
Date:06/26/2025
W. Lawrence Hawkins
Signature:/s/ W. Lawrence Hawkins
Name/Title:W. Lawrence Hawkins
Date:06/26/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement (filed herewith).

Mural Oncology PLC

NASDAQ:MURA

MURA Rankings

MURA Latest News

MURA Stock Data

42.31M
14.99M
1.62%
60.66%
2.09%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2